Scientific Advisory Board

Lewis C. Cantley, Ph.D., is Professor of Systems Biology, Chief, Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center

Linda Chin, M.D., is a co-founder of AVEOand a professor of dermatology at the Harvard Medical School, Dana-Farber Cancer Institute and an associate member of the Broad Institute of MIT and Harvard.

Ronald A. DePinho, M.D., is co-chair of the AVEO Scientific Advisory Board, one of our co-founders and has served as a director since October 2001. Dr. DePinho has served as professor of medicine and genetics at the Harvard Medical School since 1998. He is founder and director of the Belfer Institute for Applied Cancer Science and has been a member of the Departments of Medical Oncology, Medicine and Genetics at the Dana-Farber Cancer Institute and Harvard Medical School since 1998. Dr. DePinho is a leading cancer researcher, recipient of numerous awards, and currently serves on a number of advisory boards for the public and private sectors. He is a member of the Institute of Medicine of the National Academies. He holds a B.S. in Biology from Fordham University and an M.D. with distinction in Microbiology and Immunology from the Albert Einstein College of Medicine.

Douglas Hanahan, Ph.D., currently holds joint appointments in Lausanne, Switzerland and San Francisco, California. He is an American Cancer Society research professor in the department of biochemistry and biophysics, and a member of the Comprehensive Cancer Center and the Diabetes Center at the University of California San Francisco. In addition, he is the director of the Swiss Institute for Experimental Cancer Research and a professor of Molecular Oncology at the Swiss Federal Institute of Technology Lausanne.

H. Robert Horvitz, Ph.D., received the Nobel Prize in Physiology for Medicine in 2002. He is the David H. Koch professor of biology at the Massachusetts Institute of Technology; an investigator of the Howard Hughes Medical Institute; neurobiologist (neurology) at the Massachusetts General Hospital; and a members of the MIT McGovern Institute for Brain Research and the MIT Koch Institute for Integrative Cancer Research.

Tyler Jacks, Ph.D. is director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. He is also a professor of biology at MIT and an investigator of the Howard Hughes Medical Institute.

Steven C. Clark, Ph.D., served as chief scientific officer at AVEO from 2001 to 2007 and has 28 years of drug discovery experience, including seven years as vice president of research at Genetics Institute and five years as vice president of discovery research at Wyeth.

Raju Kucherlapati, Ph.D. has been a professor of Medicine at Harvard Medical School since 2001 and served as scientific director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics from 2001 to 2008. Dr. Kucherlapati was a founder of Cell Genesys, Inc., Abgenix, Inc. and Millennium Pharmaceuticals, Inc. and currently serves on the board of Enlight Biosciences LLC. Dr. Kucherlapati holds a B.S. in Biology from P.R. College, Kakinada, India, an M.S. in biology from Andhra University, Waltair, India and a Ph.D. from the University of Illinois at Urbana.

David M. Livingston, M.D., is deputy director of the Dana-Farber/Harvard Cancer Center, chief of the Charles A. Dana Division of Cancer Genetics, and the Emil Frei Professor of Genetics and Medicine at Harvard Medical School.

Murray Robinson, Ph.D., is co-chair of the AVEO Scientific Advisory Board and senior vice president, translational medicine of our company. He joined AVEO in 2003 after 12 years at Amgen, Inc. where he started and managed Amgen’s internal cancer research program.

Charles L. Sawyers, M.D., is an investigator of the Howard Hughes Medical Institute and the inaugural director of the HOPP at Memorial Sloan Kettering Cancer Center, where he is building a program of lab-based translational researchers across various clinical disciplines and institutional infrastructure to enhance the application of global genomics tools to clinical trials.